Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2017

  • ID: 4426919
  • Report
  • 101 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Clevexel Pharma SAS
  • Japan Tobacco Inc
  • LSK BioPartners Inc
  • MORE
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 5, 11 and 4 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Vitiligo, Diffuse Large B-Cell Lymphoma, Inflammation, Mantle Cell Lymphoma, Allergic Conjunctivitis, Androgenic Alopecia, Arthritis, Asthma, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Respiratory Tract Inflammatory Disorders, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia.

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Clevexel Pharma SAS
  • Japan Tobacco Inc
  • LSK BioPartners Inc
  • MORE
Introduction

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Japan Tobacco Inc

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Pfizer Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Vectura Group Plc

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles

ARN-4079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-944X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7536 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSK-9985 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06651600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Autoimmune Diseases and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-3504 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VR-588 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: New Ulcerative Colitis Data for XELJANZ (tofacitinib)at Upcoming Gastroenterology Congresses

Sep 08, 2017: NICE issues positive recommendation for XELJANZ (tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis

Aug 28, 2017: Studies reveal how shingles vaccine should be used in arthritis patients

Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis

Aug 03, 2017: Fda Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis

Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata

Jul 13, 2017: Pfizer Announces FDA Accepts Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL

Jun 16, 2017: Pfizer Announces Results From XELJANZ (Tofacitinib Citrate) Oral Strategy Study Published In The Lancet And Presented At The EULAR Annual Congress

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma

May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis

May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis

May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Aclaris Therapeutics Inc, H2 2017

Pipeline by Arrien Pharmaceuticals LLC, H2 2017

Pipeline by Astellas Pharma Inc, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by Chipscreen Biosciences Ltd, H2 2017

Pipeline by Clevexel Pharma SAS, H2 2017

Pipeline by Japan Tobacco Inc, H2 2017

Pipeline by LSK BioPartners Inc, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by MYOS RENS Technology Inc, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Portola Pharmaceuticals Inc, H2 2017

Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Pipeline by Simcere Pharmaceutical Group, H2 2017

Pipeline by Theravance Biopharma Inc, H2 2017

Pipeline by Vectura Group Plc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aclaris Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Chipscreen Biosciences Ltd
  • Clevexel Pharma SAS
  • Japan Tobacco Inc
  • LSK BioPartners Inc
  • Merck & Co Inc
  • MYOS RENS Technology Inc
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sienna Biopharmaceuticals Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Vectura Group Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll